Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Revenue of Portage Biotech Inc. (PRTG)
Revenue in 2024 (TTM): $
According to Portage Biotech Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Portage Biotech Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $ | $-54,000 | $-18,199,000 | $-85,697,000 | $-75,339,000 |
| 2023 | $ | $-1,000 | $-15,775,000 | $-122,522,000 | $-104,611,000 |
| 2022 | $ | $ | $ | $-14,817,000 | $-19,169,000 |
| 2021 | $ | $ | $ | $-14,892,000 | $-17,189,000 |
| 2020 | $ | $ | $ | $-5,084,000 | $-7,249,000 |
| 2019 | $ | $ | $-650,000 | $-3,594,000 | $-2,635,000 |
| 2018 | $ | $ | $-2,067,000 | $123.74 M | $123.74 M |
| 2017 | $ | $ | $-35,331,000 | $-641,274 | $16.3 M |
| 2016 | $ | $ | $-5 | $-9,195,389 | $-5,706,189 |
| 2015 | $ | $ | $-4,317,058 | $-4,341,216 | $-3,118,431 |
| 2014 | $ | $ | $-6,625,471 | $-6,626,630 | $-6,304,947 |
| 2013 | $98.41 K | $98.41 K | $-1,468,043 | $-1,446,578 | $-1,446,578 |
| 2012 | $ | $ | $-2,484,857 | $-3,261,525 | $-2,476,048 |
| 2011 | $ | $ | $-3,711,291 | $-4,286,724 | $-3,836,083 |
| 2010 | $ | $ | $-3,295,838 | $-3,420,602 | $-3,852,505 |
| 2009 | $41.92 K | $41.92 K | $-492,608 | $-594,015 | $-545,985 |
| 2008 | $241.38 K | $241.38 K | $-553,150 | $-625,157 | $-555,522 |
| 2007 | $644.75 K | $644.75 K | $-489,704 | $426.55 K | $-142,201 |
| 2006 | $1.59 M | $1.59 M | $-2,341,442 | $-9,188,007 | $-4,104,420 |
| 2005 | $311.46 K | $311.46 K | $-4,013,457 | $-3,718,115 | $-4,180,026 |
| 2004 | $ | $ | $-1,040,240 | $-1,035,293 | $-1,037,933 |
| 2003 | $10.39 K | $10.39 K | $-216,595 | $-207,482 | $-217,582 |
| 2002 | $41.92 K | $41.92 K | $-646,200 | $-830,361 | $-835,742 |
| 2001 | $76.14 K | $76.14 K | $-342,014 | $-1,093,207 | $-1,089,596 |
| 2000 | $21.01 K | $-935,959 | $-942,479 | $ | $-957,259 |
| 1999 | $ | $ | $-304,294 | $ | $-316,503 |
| 1998 | $ | $ | $-378,116 | $ | $-396,643 |